SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pleasanton, CA, USA - Feb 21, 2024: Exterior view of the headquarters of Roche Molecular Diagnostics (RMD) in Pleasanton, California. F. Hoffmann-La Roche AG is a Swiss pharmaceutical company.
Lung cancer
Roche Spends $570M on Another ADC Agreement With China’s MediLink
Roche first partnered with MediLink in January 2024, likewise for an antibody-drug conjugate for solid tumors.
January 9, 2026
 · 
1 min read
 · 
Tristan Manalac
Handmade signboard with Closed inscription and striped rope hanging on pin on bright red background
Layoffs
Rampart Closes Down Less Than 2 Years After Launch
Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.
January 9, 2026
 · 
1 min read
 · 
Tristan Manalac
Pictured: San Francisco’s Union Square/iStock, tra
Mergers & acquisitions
At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun
Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a break after a few tough years.
January 9, 2026
 · 
4 min read
 · 
Annalee Armstrong
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Layoffs
InflaRx Stanches Spending With 30% Staff Reduction, Priority Pivot
Aside from the layoffs, InflaRx will deprioritize Gohibic, a COVID-19 antibody that was granted emergency use authorization in 2023. The therapy failed a late-stage trial in a rare skin disease last year.
January 9, 2026
 · 
1 min read
 · 
Tristan Manalac
Trendy halftone business concept collage. Idea concept, business concept, financial planning,financial profit, favorable conditions, favorable conditions. Trendy modern retro illustration in bright trendy colors. Vector illustration
Mergers & acquisitions
Revolution Soars Amid Swirling Buyout Rumors With Merck, AbbVie
Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect many such deals to be announced.
January 9, 2026
 · 
1 min read
 · 
Tristan Manalac
Retro styled image of a set of different colorful alarm clocks
Complete response letters
Vanda Slides After FDA Again Rejects Hetlioz For Jet Lag
The DC-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for Hetlioz and promised to keep pushing for an approval.
January 8, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Hands offering money with a circular chart at the center, symbolizing shareholder equity, crowdfunding, business partnerships, and investments
IPO
UPDATE: Aktis To Become First Biotech IPO of 2026 With $318M Debut
Eli Lilly has expressed interest in participating in the IPO, with the regulatory filing revealing the obesity juggernaut’s plans to buy as much as $100 million worth of Aktis shares.
January 8, 2026
 · 
2 min read
 · 
Annalee Armstrong
Insights
From Nuclear Winter to Renewal: Biotech Investing for 2026
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.
January 8, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Trendy halftone business concept collage. Idea concept, business concept, financial planning,profit, earnings. Trendy modern retro illustration. Vector illustration
Venture capital
Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug
A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, EpiBiologics, Beacon Therapeutics and Protege.
January 8, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS